Neurogene Q2 2024 GAAP EPS $(1.09) Misses $(1.06) Estimate
Portfolio Pulse from Benzinga Newsdesk
Neurogene (NASDAQ:NGNE) reported a Q2 2024 GAAP EPS of $(1.09), missing the analyst consensus estimate of $(1.06) by 2.83%.
August 09, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Neurogene reported a Q2 2024 GAAP EPS of $(1.09), missing the analyst consensus estimate of $(1.06) by 2.83%. This miss could lead to a short-term negative impact on the stock price.
The reported EPS miss, although small, is likely to be viewed negatively by investors, potentially leading to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100